Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer Hot On The Trail Of Astellas As Menopause Drug Flies In Phase III

Executive Summary

Astellas’s fezolinetant is already on the market but Bayer is confident its non-hormonal menopause drug elinzanetant will be able to catch up on the back of demonstrating significant reductions in the frequency and severity of hot flashes in a couple of Phase III trials.

You may also be interested in...



Bayer Talks Up Pharma Prospects Post-Xarelto

The pharmaceutical division is expected to be the three-pillared German group's primary growth driver for the foreseeable future and the launch of new cardiovascular and woman's health products should help manage the loss of exclusivity on Bayer's biggest earner.

Bayer Boss Rules Out Divisions Split For Now

CEO Bill Anderson says that while the troubled Leverkusen-headquartered group operates three healthy businesses, it has been "badly broken in four places.”

Bayer’s Pipeline Refresh Focuses On Early Stage Despite Near-Term Growth Needs

The company is struggling to grow revenue, and the biggest of its four key late-stage assets had a setback, but novel technologies are fueling an R&D strategy shift towards high potential programs.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC149589

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel